Thirty-two children with retinoblastoma (RTB) were treated in our oncology unit between September 1981 and October 1989. There were 18 unilateral RTB and 14 bilateral. The median age at diagnosis was 24 months. Leukocoria was the most common sign of presentation (66%). All patients were treated with a protocol based on Reese-Ellsworth classification and the anatomo-clinic extension. Thirty patients were enucleated (7 bilaterally), 14 of which needed coadjuvant chemotherapy and 6 orbital radiotherapy. Two patients died, one from each group. The disease-free survival rate is 90.6% with a medium follow-up of 43.5 months. Seven children went blind because of bilateral enucleation and seven present facial deformity caused by radiotherapy. We underline the importance of improving the effectiveness of conservative treatment in order to reduce the number of enucleation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
De Novo RB1 Germline Variant in Retinoblastoma with Two Subsequent Independent Neoplasms: Case Report and Literature Review.
Int J Mol Sci
November 2024
Human Genetics PhD Program, Department of Molecular Biology and Genomics, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Variants in the gene are associated with retinoblastoma (RB) development, and their presence in germline cells considerably increases the risk of subsequent malignant neoplasms (SMNs) in RB survivors. We report a female patient with bilateral RB who developed two SMNs in less than ten years, with a de novo pathogenic nonsense variant in [NM_000321.3:c.
View Article and Find Full Text PDFAcquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
Ann Oncol
January 2025
UT Southwestern Simmons Comprehensive Cancer Center, Dallas, USA. Electronic address:
Article Synopsis
- A study analyzed paired baseline and end-of-treatment circulating tumor DNA (ctDNA) samples from the MONALEESA trials to identify genetic changes in patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy (ET) or a placebo.
- The analysis included 523 samples, revealing 21 genes with significant alterations at end-of-treatment, particularly highlighting increased mutations in RB1 and SPEN in the ribociclib group, while ESR1 mutations were noted in both treatment arms.
- The findings suggest acquired genetic alterations related to treatment response and resistance, providing insights for future research on resistance mechanisms and potential systemic therapies following CDK4/6 inhibitors.
Author Correction: Establishment, characterization, and genetic profiling of patient-derived osteosarcoma cells from a patient with retinoblastoma.
Sci Rep
September 2024
Faculty of Medicine, Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Chiang Mai University, 110 Intawaroros Road, Si Phum, Muang, Chiang Mai, 50200, Thailand.
Outcome of Retinoblastoma After Implementation of National Retinoblastoma Treatment Guidelines in South Africa.
JCO Glob Oncol
August 2024
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Purpose: Retinoblastoma, a curable childhood cancer, has been identified as a tracer cancer in the WHO Global Initiative for Childhood Cancer. To document the outcomes of children with retinoblastoma in South Africa, treated as per the first prospective standard national treatment guidelines for childhood cancer in South Africa.
Patients And Methods: All children diagnosed with retinoblastoma between 2012 and 2016 in five South African pediatric oncology units were treated with a standard treatment on the basis of the International Society of Pediatric Oncology-Pediatric Oncology in Developing Countries guidelines for high-income settings.
Establishment, characterization, and genetic profiling of patient-derived osteosarcoma cells from a patient with retinoblastoma.
Sci Rep
May 2024
Faculty of Medicine, Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Chiang Mai University, 110 Intawaroros Road, Si Phum, Muang, Chiang Mai, 50200, Thailand.
Osteosarcoma is the most common malignant bone cancer in pediatric patients. Patients who respond poorly to chemotherapy experience worse clinical outcomes with a high mortality rate. The major challenge is the lack of effective drugs for these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!